Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.31 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.31 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.31 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066968 | 0.92 | KCNH2 (0.69) | MCHR1KCNH2ALDH1A1SSTR5 | |
| SCHEMBL4067112 | 0.90 | MCHR1 (0.61) | MCHR1KCNH2SSTR5 | |
| SCHEMBL4068321 | 0.89 | MCHR1 (0.56) | MCHR1KCNH2SSTR5PRKAA2 | |
| SCHEMBL4065966 | 0.89 | MCHR1 (0.59) | MCHR1KCNH2SSTR5PRKAA2 | |
| SCHEMBL4065641 | 0.88 | MCHR1 (0.59) | MCHR1KCNH2SSTR5 | |
| SCHEMBL4075292 | 0.88 | MCHR1 (0.59) | MCHR1KCNH2SSTR5 | |
| SCHEMBL4068698 | 0.88 | MCHR1 (0.59) | MCHR1KCNH2SSTR5 | |
| SCHEMBL4072007 | 0.88 | MCHR1 (0.57) | MCHR1KCNH2SSTR5PRKAA2 | |
| SCHEMBL4065640 | 0.87 | MCHR1 (0.57) | MCHR1KCNH2SSTR5 | |
| SCHEMBL4072353 | 0.85 | MCHR1 (0.52) | MCHR1KCNH2SSTR5PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | claimed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | claimed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | MCHR1 730/4885KCNH2 296/4885ALDH1A1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.